ACLARIS THERAPEUTICS

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

30 Jun 2025 06:31:48 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference

26 Jun 2025 13:01:27 By Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052

23 Jun 2025 03:59:36 By Nasdaq GlobeNewswire

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

02 Jun 2025 03:59:53 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

28 May 2025 06:20:15 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

09 May 2025 04:00:19 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

08 May 2025 03:50:51 By Nasdaq GlobeNewswire

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

29 Apr 2025 04:00:32 By Nasdaq GlobeNewswire

Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody

22 Apr 2025 03:59:08 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

04 Mar 2025 04:00:05 By Nasdaq GlobeNewswire

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

27 Feb 2025 03:59:55 By Nasdaq GlobeNewswire

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

12 Feb 2025 03:50:01 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

30 Jan 2025 13:01:21 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06 Jan 2025 13:30:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

03 Dec 2024 13:30:00 By Nasdaq GlobeNewswire

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

26 Nov 2024 13:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

19 Nov 2024 06:45:01 By NetDania Notify

NetDania - New 12 months High: ACLARIS THERAPEUTICS INC. - COMMON STOCK

18 Nov 2024 06:52:02 By NetDania Notify

Aclaris Therapeutics Announces $80 Million Private Placement

18 Nov 2024 05:10:41 By Nasdaq GlobeNewswire

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

18 Nov 2024 05:10:04 By Nasdaq GlobeNewswire